Passage Bio, Inc.
PASG
$0.3117
-$0.0145-4.45%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -17.48% | -13.71% | -17.34% | -23.94% | -33.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -28.93% | -27.31% | -21.83% | -24.34% | -29.08% |
| Operating Income | 28.93% | 27.31% | 21.83% | 24.34% | 29.08% |
| Income Before Tax | 36.54% | 38.78% | 31.61% | 33.86% | 25.02% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 36.54% | 38.78% | 31.61% | 33.86% | 25.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 36.54% | 38.78% | 31.61% | 33.86% | 25.02% |
| EBIT | 28.93% | 27.31% | 21.83% | 24.34% | 29.08% |
| EBITDA | 29.43% | 27.71% | 22.22% | 24.98% | 29.96% |
| EPS Basic | 42.38% | 42.87% | 33.88% | 34.53% | 25.45% |
| Normalized Basic EPS | 36.52% | 33.50% | 26.64% | 28.09% | 33.19% |
| EPS Diluted | 42.24% | 42.75% | 33.77% | 34.43% | 25.40% |
| Normalized Diluted EPS | 36.52% | 33.50% | 26.64% | 28.09% | 33.19% |
| Average Basic Shares Outstanding | 10.33% | 7.29% | 4.26% | 1.19% | 0.58% |
| Average Diluted Shares Outstanding | 10.33% | 7.29% | 4.26% | 1.19% | 0.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |